AR045859A1 - Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos - Google Patents
Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usosInfo
- Publication number
- AR045859A1 AR045859A1 ARP040103592A ARP040103592A AR045859A1 AR 045859 A1 AR045859 A1 AR 045859A1 AR P040103592 A ARP040103592 A AR P040103592A AR P040103592 A ARP040103592 A AR P040103592A AR 045859 A1 AR045859 A1 AR 045859A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydrogen
- cycloalkyl
- chf2
- benzodiazepinas
- Prior art date
Links
- 150000007655 dibenzoazepines Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- -1 -CH2CF Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula general (1), en donde: R es -(CHR')q-arilo o -(CHR')q-heteroarilo, que están sin sustituir o mono, di- o tri-sustituidos por alquilo inferior, alcoxilo inferior, CF3 o halógeno, o es alquilo inferior, -(CH2)n- O-alquilo inferior, -(CH2)n-S-alquilo inferior, -(CH2)q-cicloalquilo, -(CH2)n-(CH2F), (CH2)n-CF3, (CH2)n-CHF2-CF3, (CH2)n-CHF2-CHF2, (CH2)n-CR'R''-CF3, y en donde R' y R'' forman junto con el átomo de carbono un anillo cicloalquilo; R2 es hidrógeno o alquilo inferior; R3 es hidrógeno, alquilo inferior, -CH2CF, CF3, o es arilo, opcionalmente mono, di o tri-sustituidos por halógeno, o es -(CH2)nNR5R6, en donde R5 y R6 son independientemente el uno del otro hidrógeno o alquilo inferior; R4 es uno de los grupos de fórmulas (2), en donde: R7 es hidrógeno, alquilo inferior, o -(CH2)n-cicloalquilo; R8, R9 son, independientemente, hidrógeno, alquilo inferior, -(CH2)n-cicloalquilo o -C(O)-fenilo; y a sales de adición ácida farmacéuticamente aceptables, enantiómeros ópticamente puros, racematos o mezclas diastereoméricas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03022650 | 2003-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045859A1 true AR045859A1 (es) | 2005-11-16 |
Family
ID=34384575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103592A AR045859A1 (es) | 2003-10-06 | 2004-10-04 | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7166587B2 (es) |
| EP (1) | EP1673347B1 (es) |
| JP (1) | JP4503607B2 (es) |
| KR (2) | KR100867035B1 (es) |
| CN (1) | CN1894217B (es) |
| AR (1) | AR045859A1 (es) |
| AU (1) | AU2004283803B2 (es) |
| BR (1) | BRPI0415070B8 (es) |
| CA (1) | CA2541470C (es) |
| CO (1) | CO5690560A2 (es) |
| CY (1) | CY1116865T1 (es) |
| DK (1) | DK1673347T3 (es) |
| ES (1) | ES2548720T3 (es) |
| HR (1) | HRP20151197T1 (es) |
| HU (1) | HUE025548T2 (es) |
| IL (1) | IL174513A (es) |
| MX (1) | MXPA06003870A (es) |
| MY (1) | MY143797A (es) |
| NO (1) | NO20061469L (es) |
| NZ (1) | NZ546036A (es) |
| PL (1) | PL1673347T3 (es) |
| PT (1) | PT1673347E (es) |
| RU (1) | RU2356895C2 (es) |
| SI (1) | SI1673347T1 (es) |
| TW (1) | TWI293627B (es) |
| WO (1) | WO2005040126A1 (es) |
| ZA (1) | ZA200602802B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| US7816387B2 (en) * | 2005-09-05 | 2010-10-19 | Dainippon Sumitomo Pharma Co., Ltd. | β secretase inhibitor |
| EP2018368B1 (en) * | 2006-03-27 | 2012-12-05 | F. Hoffmann-La Roche AG | Malonamide derivatives as gamma secretase inhibitors |
| MX2009002538A (es) | 2006-09-20 | 2009-03-20 | Hoffmann La Roche | Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina. |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| BRPI0807341A2 (pt) | 2007-02-02 | 2014-05-20 | Hoffmann La Roche | Derivados de 6-oxo-6,7-di-hidro-5h-dibenzo[b,d]azepin-7-ila |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US7579464B2 (en) * | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
| CA2772488C (en) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| WO2011140213A1 (en) * | 2010-05-05 | 2011-11-10 | Amicus Therapeutics, Inc. | Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| KR102130458B1 (ko) * | 2015-10-30 | 2020-07-08 | 파이프라인 테라퓨틱스, 아이엔씨. | 디벤조 아제핀 화합물 및 귀 질환과 귀 장애 치료에서의 그의 용도 |
| EP3554502A4 (en) * | 2016-12-16 | 2021-01-06 | Pipeline Therapeutics, Inc. | METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US20210220372A1 (en) * | 2018-05-15 | 2021-07-22 | Bristol-Myers Squibb Company | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9314981D0 (en) * | 1993-07-20 | 1993-09-01 | Glaxo Spa | Chemical compounds |
| BR9917082A (pt) * | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase |
| CA2404273A1 (en) * | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
| CN1386118A (zh) * | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物 |
| NZ541324A (en) * | 2003-02-04 | 2008-10-31 | Hoffmann La Roche | Malonamide derivatives as gamma-secretase inhibitors |
| DE602004020680D1 (de) * | 2003-09-09 | 2009-05-28 | Hoffmann La Roche | Die aktivität von gamma-secretase blockierende malonamidderivate |
-
2004
- 2004-09-27 KR KR1020067006540A patent/KR100867035B1/ko not_active Expired - Lifetime
- 2004-09-27 JP JP2006530028A patent/JP4503607B2/ja not_active Expired - Lifetime
- 2004-09-27 WO PCT/EP2004/010821 patent/WO2005040126A1/en not_active Ceased
- 2004-09-27 BR BRPI0415070A patent/BRPI0415070B8/pt not_active IP Right Cessation
- 2004-09-27 ES ES04787028.2T patent/ES2548720T3/es not_active Expired - Lifetime
- 2004-09-27 RU RU2006115165/04A patent/RU2356895C2/ru not_active IP Right Cessation
- 2004-09-27 HR HRP20151197TT patent/HRP20151197T1/hr unknown
- 2004-09-27 PL PL04787028T patent/PL1673347T3/pl unknown
- 2004-09-27 HU HUE04787028A patent/HUE025548T2/en unknown
- 2004-09-27 EP EP04787028.2A patent/EP1673347B1/en not_active Expired - Lifetime
- 2004-09-27 DK DK04787028.2T patent/DK1673347T3/en active
- 2004-09-27 US US10/951,229 patent/US7166587B2/en not_active Expired - Lifetime
- 2004-09-27 MX MXPA06003870A patent/MXPA06003870A/es active IP Right Grant
- 2004-09-27 PT PT47870282T patent/PT1673347E/pt unknown
- 2004-09-27 CA CA2541470A patent/CA2541470C/en not_active Expired - Lifetime
- 2004-09-27 CN CN2004800333748A patent/CN1894217B/zh not_active Expired - Lifetime
- 2004-09-27 NZ NZ546036A patent/NZ546036A/en unknown
- 2004-09-27 KR KR1020087003016A patent/KR100884872B1/ko not_active Expired - Lifetime
- 2004-09-27 AU AU2004283803A patent/AU2004283803B2/en not_active Expired
- 2004-09-27 SI SI200432267T patent/SI1673347T1/sl unknown
- 2004-10-04 AR ARP040103592A patent/AR045859A1/es unknown
- 2004-10-04 TW TW093130014A patent/TWI293627B/zh active
- 2004-10-05 MY MYPI20044077A patent/MY143797A/en unknown
-
2006
- 2006-03-23 IL IL174513A patent/IL174513A/en active IP Right Grant
- 2006-03-31 NO NO20061469A patent/NO20061469L/no not_active Application Discontinuation
- 2006-04-05 ZA ZA200602802A patent/ZA200602802B/en unknown
- 2006-04-07 CO CO06034536A patent/CO5690560A2/es not_active Application Discontinuation
-
2015
- 2015-10-29 CY CY20151100963T patent/CY1116865T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR029717A1 (es) | Derivados del pro-farmaco de 4-fenil-piridina | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| AR060729A1 (es) | Compuestos agonistas de los receptores muscarinicos | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| AR070130A1 (es) | Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| ECSP066414A (es) | Derivados de malonamida que bloquean la actividad de gama-secretasa | |
| PE20090159A1 (es) | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| CO5170521A1 (es) | Compuestos farmaceuticos de pirimidinona | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| EA200701640A1 (ru) | Новые соединения с терапевтическим эффектом | |
| AR060621A1 (es) | Compuestos triarilicos y sus derivados | |
| AR044400A1 (es) | Procesos para la preparacion de derivados de pirimidina | |
| MX2009011051A (es) | Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble. | |
| AR057350A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas | |
| AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |